RAHWAY, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE) October 28, 2024 -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada,...

Using a gene signature technique to tailor chemotherapy for patients with early triple-negative breast cancer shows promise as a way to improve...

THURSDAY, Oct. 31, 2024 -- Inavolisib plus palbociclib-fulvestrant yields significantly longer progression-free survival than placebo plus...

In a new study led by Johns Hopkins Medicine, the drug RK-33 has demonstrated promise in treating breast cancer that has spread to the bone (breast...

Cutting-edge research has uncovered how chronic stress disrupts the balance of gut microbiota to speed up the progression of colorectal cancer (CRC),...

A study of patients with metastatic lung cancer by researchers based in Brazil and the United States has found that their performance in simple...

The medicine - branded Lenvima - stops cancer cells from multiplying, slowing the disease's progression.

The risks of adverse effects and complications from treatment for prostate cancer are substantial and continue for years after treatment ends.

Tokyo and Basking Ridge, NJ – (October 30, 2024) – The first patients have been dosed in three global, randomized phase 3 trials...

MONDAY, Nov. 4, 2024 -- Huntington's disease is a devastating, fatal neurological illness with little means of treatment, but a new study in mice...